Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives

Key Takeaways Explain This Topic AI

Norepinephrine is the first-line vasopressor across neurocritical care for septic shock, neurogenic shock, and cerebral perfusion pressure ( C P P CPP CPP ) augmentation, combining potent α 1 \alpha_1 α 1 ​ -mediated vasoconstriction with modest β 1 \beta_1 β 1 ​ -mediated inotropic support.

Phenylephrine provides pure α 1 \alpha_1 α 1 ​ vasoconstriction without chronotropy, making it ideal when tachyarrhythmias complicate norepinephrine titration or in dynamic left ventricular outflow tract obstruction, but it risks reflex bradycardia and decreased cardiac output.

Inodilators (dobutamine via β 1 > β 2 \beta_1 > \beta_2 β 1 ​ > β 2 ​ agonism and milrinone via phosphodiesterase-3 inhibition) augment myocardial contractility while decreasing afterload, but both carry substantial risks of systemic hypotension, reflex tachycardia, and increased myocardial oxygen consumption.

Intravenous nicardipine and clevidipine are first-line dihydropyridine calcium channel blockers for acute hypertension in stroke and intracerebral hemorrhage; clevidipine's ultra-short esterase metabolism ( t 1 / 2 ≈ 2 – 4 min t_{1/2} \approx 2\text{--}4\text{ min} t 1/2 ​ ≈ 2 – 4 min ) enables rapid, precise titration without accumulation in renal or hepatic failure.

Hydralazine can be difficult to titrate predictably, and sodium nitroprusside is generally avoided in patients with elevated intracranial pressure or mass lesions because they trigger potent cerebral arteriolar and venous vasodilation, increasing cerebral blood volume ( C B V CBV CB V ) and dangerously elevating I C P ICP I CP .

Last updated: October 2026

Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives

The hemodynamic stabilization of neurocritical care patients demands a nuanced understanding of receptor pharmacology, cardiovascular mechanics, and cerebrovascular physiology. Vasoactive agents are deployed to augment cerebral perfusion pressure ( C P P CPP CPP ), manage neurogenic and distributive shock, support neurogenic myocardial dysfunction, and strictly control arterial blood pressure in acute stroke and intracranial hemorrhage. Selecting the wrong agent can precipitate myocardial ischemia, secondary brain edema, intracranial hypertension, or fatal cerebral hypoperfusion.

Receptor Pharmacology in Hemodynamic Regulation

Vasoactive infusions exert their therapeutic and adverse effects by engaging specific cell-surface receptors across vascular smooth muscle, cardiac myocytes, and specialized conduction tissues:

Receptor Coupling & Second Messenger Primary Vascular / Cardiac Distribution Hemodynamic Effect Neuro-ICU Relevance

α 1 \alpha_1 α 1 ​ Adrenergic G q → PLC → IP 3 + DAG → ↑ Ca 2 + G_q \to \text{PLC} \to \text{IP}_3 + \text{DAG} \to \uparrow\text{Ca}^{2+} G q ​ → PLC → IP 3 ​ + DAG →↑ Ca 2 + Vascular smooth muscle (arteriolar and venous) Potent vasoconstriction, ↑ SVR \uparrow\text{SVR} ↑ SVR , ↑ \uparrow ↑ venous return (preload) Primary target for raising M A P MAP M A P and augmenting C P P CPP CPP

α 2 \alpha_2 α 2 ​ Adrenergic G i → ↓ cAMP G_i \to \downarrow\text{cAMP} G i ​ →↓ cAMP Presynaptic sympathetic terminals, brainstem ( R V L M RVLM R V L M ) Inhibits norepinephrine release, ↓ \downarrow ↓ sympathetic outflow Central agonism (dexmedetomidine, clonidine) causes bradycardia and hypotension

β 1 \beta_1 β 1 ​ Adrenergic G s → ↑ Adenylyl Cyclase → ↑ cAMP → PKA G_s \to \uparrow\text{Adenylyl Cyclase} \to \uparrow\text{cAMP} \to \text{PKA} G s ​ →↑ Adenylyl Cyclase →↑ cAMP → PKA Cardiac myocytes, SA and AV nodes ↑ \uparrow ↑ Inotropy, ↑ \uparrow ↑ chronotropy, ↑ \uparrow ↑ dromotropy Improves stroke volume; increases myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ​ ) and arrhythmia risk

β 2 \beta_2 β 2 ​ Adrenergic G s → ↑ Adenylyl Cyclase → ↑ cAMP G_s \to \uparrow\text{Adenylyl Cyclase} \to \uparrow\text{cAMP} G s ​ →↑ Adenylyl Cyclase →↑ cAMP Vascular smooth muscle, bronchial smooth muscle, hepatocytes Vasodilation, bronchodilation, ↑ \uparrow ↑ glycogenolysis Decreases S V R SVR S V R ; induces hyperlactatemia via aerobic glycolysis

V 1 V_1 V 1 ​ ( V 1 a V_{1a} V 1 a ​ ) G q → PLC → ↑ Ca 2 + G_q \to \text{PLC} \to \uparrow\text{Ca}^{2+} G q ​ → PLC →↑ Ca 2 + Vascular smooth muscle Potent vasoconstriction (independent of adrenergic receptors) Effective in refractory acidemic shock; spares adrenergic burden; treats central DI

D A 1 DA_1 D A 1 ​ G s → ↑ cAMP G_s \to \uparrow\text{cAMP} G s ​ →↑ cAMP Renal, mesenteric, coronary, and cerebral vessels Vasodilation of specific beds at low doses ( < 3 μ g/kg/min < 3\ \mu\text{g/kg/min} < 3 μ g/kg/min ) Minimal proven benefit for renal protection; largely supplanted by norepinephrine

• Vasopressors and Inotropes in the Neuro-ICU
• Norepinephrine ( α 1 > β 1 \alpha_1 > \beta_1 α 1 ​ > β 1 ​ )

Mechanism: Potent α 1 \alpha_1 α 1 ​ agonist with modest β 1 \beta_1 β 1 ​ inotropic activity and minimal β 2 \beta_2 β 2 ​ effect.

Hemodynamic Profile: Increases systemic vascular resistance ( S V R SVR S V R ), arterial blood pressure, and effective circulating volume (via venoconstriction of capacitance vessels). Stroke volume is generally preserved or slightly increased due to enhanced venous return and direct inotropy, counterbalancing increased afterload.

Clinical Role: First-line vasopressor for septic shock, neurogenic shock, traumatic brain injury, and induced hypertension for delayed cerebral ischemia ( D C I DCI D C I ) in subarachnoid hemorrhage.

Dosing: 0.01 – 3.0 μ g/kg/min 0.01\text{--}3.0\ \mu\text{g/kg/min} 0.01 – 3.0 μ g/kg/min (or 1 – 30 μ g/min 1\text{--}30\ \mu\text{g/min} 1 – 30 μ g/min ), titrated to target M A P MAP M A P or C P P CPP CPP .

Phenylephrine (Pure α 1 \alpha_1 α 1 ​ )

Mechanism: Pure synthetic α 1 \alpha_1 α 1 ​ agonist completely devoid of direct β \beta β -adrenergic activity.

Hemodynamic Profile: Induces rapid, intense arteriolar vasoconstriction, sharply increasing S V R SVR S V R and M A P MAP M A P .

Clinical Pitfall & Role: The abrupt increase in afterload coupled with the absence of β 1 \beta_1 β 1 ​ chronotropy triggers a prominent baroreceptor-mediated reflex bradycardia . In patients with underlying left ventricular dysfunction, phenylephrine can cause a marked reduction in stroke volume and cardiac index.

Indications: Indicated when norepinephrine is limited by severe tachyarrhythmias, or in patients with dynamic left ventricular outflow tract ( L V O T LVOT L V OT ) obstruction (Takotsubo cardiomyopathy) where inotropy must be avoided.

Vasopressin ( V 1 V_1 V 1 ​ Agonist)

Mechanism: Exogenous arginine vasopressin activates vascular V 1 V_1 V 1 ​ receptors, stimulating phospholipase C and mobilizing intracellular calcium.

Hemodynamic Profile: Causes intense vasoconstriction without direct adrenergic stimulation. Unlike catecholamines, vasopressin remains biologically active in the presence of severe lactic acidosis and hypoxia.

Clinical Role: Second-line catecholamine-sparing agent in septic and neurogenic shock. Particularly valuable in neuro-ICU patients who develop central diabetes insipidus ( D I DI D I ) following pituitary surgery or severe traumatic brain injury, simultaneously resolving polyuria and supporting blood pressure.

Dosing & Caution: Administered as a fixed, non-titrated continuous infusion at 0.03 – 0.04 units/min 0.03\text{--}0.04\text{ units/min} 0.03 – 0.04 units/min . Titrating above 0.04 units/min 0.04\text{ units/min} 0.04 units/min increases the risk of severe splanchnic hypoperfusion, coronary vasospasm, and digital gangrene.

Epinephrine ( β 1 , β 2 \beta_1, \beta_2 β 1 ​ , β 2 ​ at low doses; α 1 \alpha_1 α 1 ​ at higher doses)

Mechanism: Non-selective adrenergic agonist. At low doses ( < 0.05 μ g/kg/min < 0.05\ \mu\text{g/kg/min} < 0.05 μ g/kg/min ), β 1 \beta_1 β 1 ​ and β 2 \beta_2 β 2 ​ effects predominate, increasing cardiac contractility, heart rate, and cardiac output while mildly reducing S V R SVR S V R . At higher doses ( > 0.1 μ g/kg/min > 0.1\ \mu\text{g/kg/min} > 0.1 μ g/kg/min ), α 1 \alpha_1 α 1 ​ effects predominate, producing intense vasoconstriction.

Clinical Role: Second-line agent for refractory cardiogenic or distributive shock and anaphylaxis.

Metabolic Pitfall: Epinephrine stimulates skeletal muscle β 2 \beta_2 β 2 ​ receptors, activating membrane-bound Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pumps and accelerating cellular glycolysis. This produces excess pyruvate that exceeds pyruvate dehydrogenase capacity, converting into lactate ( Type B aerobic hyperlactatemia ). This pharmacologic hyperlactatemia must not be misinterpreted as worsening tissue hypoperfusion.

Inodilators: Dobutamine and Milrinone

Inodilators are deployed in the neuro-ICU primarily to manage neurogenic stunned myocardium ( N S M NSM NSM ) , Takotsubo cardiomyopathy with cardiogenic shock, and acute left ventricular decompensation.

Feature Dobutamine Milrinone

Primary Mechanism Synthetic β 1 > β 2 \beta_1 > \beta_2 β 1 ​ > β 2 ​ agonist Phosphodiesterase-3 (PDE-3) inhibitor ( ↓ \downarrow ↓ cAMP breakdown)

Inotropic Action Potent direct inotropy; increases M V O 2 MVO_2 M V O 2 ​ Potent inotropy; independent of β \beta β -receptor downregulation

Vascular Effect Mild β 2 \beta_2 β 2 ​ vasodilation; may cause hypotension Marked systemic and pulmonary arteriolar vasodilation

Pharmacokinetics Rapid onset; half-life 2 – 3 minutes 2\text{--}3\text{ minutes} 2 – 3 minutes Half-life 2 – 4 hours 2\text{--}4\text{ hours} 2 – 4 hours ; renally cleared

Key Adverse Effects Tachyarrhythmias, ventricular ectopy, angina Systemic hypotension, ventricular arrhythmias, drug accumulation in renal failure

Neuro-ICU Use Titratable support for acute low cardiac output Inotropy plus pulmonary afterload reduction; cerebral vasospasm dilation

Warning

Both dobutamine and milrinone reduce systemic vascular resistance. In volume-depleted or vasodilated patients, initiating these agents without concurrent vasopressor support (e.g., norepinephrine) can trigger severe arterial hypotension, collapsing cerebral perfusion pressure ( C P P CPP CPP ). Furthermore, inodilators are strictly contraindicated in patients with dynamic L V O T LVOT L V OT obstruction.

Intravenous Antihypertensive Agents

Rapid, titratable blood pressure reduction is essential in acute ischemic stroke ( A I S AIS A I S ), spontaneous intracerebral hemorrhage ( I C H ICH I C H ), and pre-securing aneurysmal subarachnoid hemorrhage ( a S A H aSAH a S A H ).

Nicardipine

Mechanism: Dihydropyridine L-type calcium channel blocker with high selectivity for vascular smooth muscle over cardiac tissue.

Hemodynamic Profile: Rapid systemic arteriolar vasodilation with minimal to no negative inotropic or dromotropic effect. It produces a predictable, smooth dose-dependent reduction in blood pressure without sudden precipitously low troughs.

Cerebrovascular Effects: Dilates cerebral vessels without increasing intracranial pressure at therapeutic doses, making it the premier continuous infusion across neurovascular emergencies.

Titration: Initiate at 5 mg/h 5\text{ mg/h} 5 mg/h IV; titrate by 2.5 mg/h 2.5\text{ mg/h} 2.5 mg/h every 5–15 minutes to target (maximum 15 mg/h 15\text{ mg/h} 15 mg/h ). Once target is achieved, reduce infusion rate to 3 mg/h 3\text{ mg/h} 3 mg/h for maintenance.

Clevidipine

Mechanism: Third-generation, ultra-short-acting dihydropyridine calcium channel blocker formulated in a 20 % 20\% 20% lipid emulsion.

Pharmacokinetics: Metabolized by non-specific blood and tissue esterases. It exhibits an ultra-rapid onset ( 2 – 4 minutes 2\text{--}4\text{ minutes} 2 – 4 minutes ) and offset ( 5 – 15 minutes 5\text{--}15\text{ minutes} 5 – 15 minutes ), independent of hepatic or renal function.

Advantages in Neuro-ICU: Unparalleled minute-by-minute titration precision. In acute stroke patients undergoing thrombolysis or EVT, clevidipine allows rapid attainment of the < 180 / 105 mmHg < 180/105\text{ mmHg} < 180/105 mmHg target without risk of prolonged "overshoot" hypotension that could infarct the ischemic penumbra.

Dosing & Safety: Start at 1 – 2 mg/h 1\text{--}2\text{ mg/h} 1 – 2 mg/h ; double dose every 90 seconds until near target, then titrate in smaller increments up to 32 mg/h 32\text{ mg/h} 32 mg/h . Because it is formulated in a lipid emulsion ( 2 kcal/mL 2\text{ kcal/mL} 2 kcal/mL ), strict aseptic handling, vial changes every 12 hours, and monitoring for hypertriglyceridemia are required. Contraindicated in severe egg or soy allergy.

Labetalol

Mechanism: Combined selective α 1 \alpha_1 α 1 ​ and non-selective β 1 / β 2 \beta_1/\beta_2 β 1 ​ / β 2 ​ adrenergic antagonist. When administered intravenously, the ratio of α \alpha α -to- β \beta β blockade is approximately 1 : 7 1:7 1 : 7 .

Hemodynamic Profile: Decreases systemic vascular resistance via α 1 \alpha_1 α 1 ​ antagonism while blunting reflex tachycardia and decreasing myocardial contractility via β 1 \beta_1 β 1 ​ antagonism.

Clinical Role: Ideal for patients presenting with simultaneous acute hypertension and sinus tachycardia. Often administered as intermittent boluses ( 10 – 20 mg 10\text{--}20\text{ mg} 10 – 20 mg IV over 2 minutes, repeating or doubling every 10 minutes up to 300 mg 300\text{ mg} 300 mg total) or as a continuous infusion ( 1 – 8 mg/min 1\text{--}8\text{ mg/min} 1 – 8 mg/min ).

Contraindications: Second- or third-degree heart block, severe sinus bradycardia ( HR < 60 bpm \text{HR} < 60\text{ bpm} HR < 60 bpm ), acute decompensated systolic heart failure, and active severe reactive airway disease (bronchospasm).

Hazardous Vasodilators in Neurocritical Care: Hydralazine & Nitroprusside

Warning

Hydralazine and Sodium Nitroprusside Precipitate Intracranial Hypertension:

Direct-acting vasodilators like hydralazine and sodium nitroprusside are hazardous in patients with acute intracranial mass lesions, severe cerebral edema, or impaired intracranial compliance:

Cerebral Vasodilation & Increased CBV: Both agents cause profound dilation of cerebral resistance arterioles and venous capacitance vessels. This expands cerebral blood volume ( C B V CBV CB V ), producing steep, unpredictable spikes in intracranial pressure ( I C P ICP I CP ) and precipitating transtentorial herniation in vulnerable patients.

Unpredictable Kinetics of Hydralazine: Intravenous hydralazine has a prolonged, highly unpredictable onset ( 10 – 30 minutes 10\text{--}30\text{ minutes} 10 – 30 minutes ) and duration of action ( 2 – 8 hours 2\text{--}8\text{ hours} 2 – 8 hours ). Repeated intermittent boluses frequently lead to dose stacking and severe, refractory overshoot hypotension, compromising C P P CPP CPP .

Nitroprusside Toxicity & Steal Phenomenon: Sodium nitroprusside releases nitric oxide directly. In addition to elevating I C P ICP I CP , it causes intracerebral "steal" (diverting blood from ischemic penumbral tissue to normal brain regions) and breaks down into toxic cyanide and thiocyanate metabolites during prolonged or high-dose infusions.

Clinical Rule: In the neuro-ICU, manage acute hypertension with titratable calcium channel blockers (nicardipine, clevidipine) or labetalol; avoid hydralazine and nitroprusside.